Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) – Equities research analysts at Cantor Fitzgerald increased their FY2019 earnings per share (EPS) estimates for Zynerba Pharmaceuticals in a research note issued on Wednesday, March 13th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings of ($2.22) per share for the year, up from their previous estimate of ($2.77). Cantor Fitzgerald has a “Buy” rating and a $11.00 price objective on the stock.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings results on Monday, March 11th. The company reported ($0.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.21. The company had revenue of $0.09 million during the quarter.
Several other research firms also recently commented on ZYNE. ValuEngine downgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research note on Saturday, January 19th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Zynerba Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $13.38.
ZYNE stock opened at $4.97 on Friday. The stock has a market capitalization of $103.24 million, a P/E ratio of -1.90 and a beta of 4.93. Zynerba Pharmaceuticals has a 12 month low of $2.75 and a 12 month high of $12.50.
A number of hedge funds and other institutional investors have recently bought and sold shares of ZYNE. Virtu Financial LLC purchased a new position in Zynerba Pharmaceuticals during the 4th quarter valued at about $40,000. Two Sigma Investments LP purchased a new position in Zynerba Pharmaceuticals during the 4th quarter valued at about $120,000. Thompson Siegel & Walmsley LLC purchased a new position in Zynerba Pharmaceuticals during the 3rd quarter valued at about $157,000. GSA Capital Partners LLP purchased a new position in Zynerba Pharmaceuticals during the 3rd quarter valued at about $177,000. Finally, Zeke Capital Advisors LLC purchased a new position in Zynerba Pharmaceuticals during the 3rd quarter valued at about $193,000. 15.39% of the stock is currently owned by institutional investors and hedge funds.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
See Also: Gap Up Stocks
Receive News & Ratings for Zynerba Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.